Table 4.
Hazard ratios and 95% confidence intervals for associationsa of each of the 9 components of the 2-year post-diagnosis lifestyle score with all-cause mortality, breast cancer-mortality, and breast cancer recurrence.
| All-Cause Mortality | Breast Cancer-Specific Mortality | Breast Cancer Recurrence | |||||
|---|---|---|---|---|---|---|---|
| Recommendation | Category | # Events | HR (95% CI) | # Events | HR (95% CI) | # Events | HR (95% CI) |
| Fruits/Vegetables | Tertile 1 (0–3.33 svg/d) | 84 | 1.00 (–) | 30 | 1.00 (–) | 45 | 1.00 (–) |
| Tertile 2 (3.33–5.56 svg/d) | 89 | 1.25 (0.92, 1.70) | 26 | 0.95 (0.54, 1.67) | 52 | 1.23 (0.82, 1.86) | |
| Tertile 3 (5.56+ svg/d) | 69 | 1.20 (0.85, 1.69) | 14 | 0.79 (0.40, 1.58) | 55 | 1.49 (0.97, 2.28) | |
| per 2 svg/d increase | 1.02 (0.92, 1.12) | 0.94 (0.76, 1.16) | 1.09 (0.98, 1.21) | ||||
| Legumes | Tertile 1 (0–0.09 svg/d) | 103 | 1.00 (–) | 38 | 1.00 (–) | 53 | 1.00 (–) |
| Tertile 2 (0.09–0.32 svg/d) | 79 | 0.92 (0.68, 1.25) | 17 | 0.53 (0.10, 2.75) | 56 | 0.97 (0.66, 1.43) | |
| Tertile 3 (0.32+ svg/d) | 60 | 0.66 (0.47, 0.94) | 15 | 0.57 (0.29, 1.11) | 43 | 0.67 (0.43, 1.02) | |
| per 2 svg/d increase | 0.40 (0.18, 0.89) | 0.53 (0.10, 2.75) | 0.48 (0.20, 1.14) | ||||
| % of grains that are whole | Tertile 1 (0–12.5%) | 83 | 1.00 (–) | 26 | 1.00 (–) | 49 | 1.00 (–) |
| Tertile 2 (12.5–30.0%) | 79 | 1.15 (0.84, 1.59) | 20 | 1.08 (0.57, 2.03) | 55 | 1.09 (0.73, 1.62) | |
| Tertile 3 (>30.0%) | 80 | 1.14 (0.83, 1.59) | 24 | 1.24 (0.67, 2.28) | 48 | 0.99 (0.65, 1.51) | |
| Per 2% increase | 1.00 (0.99, 1.02) | 1.00 (0.97, 1.03) | 1.00 (0.98, 1.02) | ||||
| % calories from saturated fats | Tertile 1 (<9.5%) | 77 | 1.00 (–) | 22 | 1.00 (–) | 47 | 1.00 (–) |
| Tertile 2 (9.5–11.8%) | 76 | 0.86 (0.62, 1.20) | 16 | 0.47 (0.23, 0.93) | 52 | 1.05 (0.70, 1.58) | |
| Tertile 3 (>11.8%) | 89 | 1.05 (0.75, 1.46) | 32 | 1.14 (0.63, 2.07) | 53 | 1.13 (0.74, 1.71) | |
| Per 2% increase | 1.03 (0.92, 1.14) | 1.12 (0.93, 1.35) | 1.03 (0.90, 1.17) | ||||
| Alcohol | Nondrinker | 32 | 1.00 (–) | 10 | 1.00 (–) | 17 | 1.00 (–) |
| ≤1 drink/d | 172 | 0.81 (0.54, 1.20) | 48 | 0.74 (0.36, 1.55) | 104 | 0.74 (0.44, 1.25) | |
| >1 drink/d | 38 | 0.70 (0.42, 1.15) | 12 | 0.72 (0.29, 1.81) | 31 | 0.88 (0.47, 1.64) | |
| Per 2 drinks/d increase | 0.95 (0.69, 1.29) | 0.99 (0.55, 1.79) | 1.01 (0.70, 1.48) | ||||
| Aerobic | 0 MET hrs/wk | 112 | 1.00 (–) | 35 | 1.00 (–) | 39 | 1.00 (–) |
| 0-<8.75 MET hrs/wk | 49 | 0.58 (0.41, 0.83) | 12 | 0.65 (0.32, 1.32) | 38 | 0.85 (0.53, 1.37) | |
| 8.75+ MET hrs/wk | 81 | 0.55 (0.39, 0.76) | 23 | 1.07 (0.58, 1.98) | 75 | 0.84 (0.54, 1.31) | |
| Per 3.5 MET hr/wk increase | 0.97 (0.94, 1.00) | 1.03 (0.97, 1.09) | 0.98 (0.94, 1.01) | ||||
| Strength | None | 174 | 1.00 (–) | 57 | 1.00 (–) | 89 | 1.00 (–) |
| 1–2x/wk | 24 | 0.63 (0.41, 0.98) | 3 | 0.26 (0.08, 0.86) | 24 | 0.81 (0.50, 1.29) | |
| >2x/wk | 44 | 0.99 (0.69, 1.42) | 10 | 0.84 (0.40, 1.76) | 39 | 1.26 (0.84, 1.90) | |
| Sedentary | Tertile 1 (0–14.4 hr/wk) | 73 | 1.00 (–) | 21 | 1.00 (–) | 54 | 1.00 (–) |
| Tertile 2 (14.5–20.9 hr/wk) | 76 | 0.91 (0.65, 1.27) | 19 | 0.64 (0.33, 1.24) | 46 | 0.90 (0.60, 1.35) | |
| Tertile 3 (>21–54 hr/wk) | 93 | 0.93 (0.67, 1.30) | 30 | 0.88 (0.48, 1.62) | 52 | 0.97 (0.64, 1.46) | |
| Per 2hr/wk increase | 0.98 (0.95, 1.01) | 0.97 (0.91, 1.03) | 1.00 (0.96, 1.04) | ||||
| Body Weightb | Normal-Normal | 61 | 1.00 (–) | 11 | 1.00 (–) | 38 | 1.00 (–) |
| Other | 97 | 1.17 (0.84, 1.63) | 26 | 1.07 (0.53, 2.17) | 70 | 1.30 (0.87, 1.92) | |
| Obese-obese or overweight-obese | 84 | 1.21 (0.85, 1.73) | 33 | 2.50 (1.27, 4.91) | 44 | 1.14 (0.73, 1.79) | |
Abbreviations: CI, confidence intervals; d, days; HR, hazard ratio; hr, hours; svg, servings; wk, week
a
Model includes all 9 recommendations together in a multivariable Cox model and additionally adjusts for age, tumor stage, ER status, chemotherapy, Herceptin, radiation, comorbidities, smoking status, income, and education level. Mortality cohort (n= 1,736); Recurrence cohort (n=1,705). No collinearity issues were identified.
b
Body weight at baseline and 2-years post-diagnosis.